Source comparison
ARA-290 and BPC-157: Evidence Comparison
ARA-290 Innate repair receptor activation (CD131/EPOR heterodimer) Phase 2b completed Increased intraepidermal nerve fibre density in sarcoidosis-associated neuropathy (statistically significant vs placebo) Peripheral nerves, CNS, cardiac tissue Moderate. Rand
This comparison does not assign a generated winner or score.
- ARA-290
- Innate repair receptor activation (CD131/EPOR heterodimer)
- Phase 2b completed
- Increased intraepidermal nerve fibre density in sarcoidosis-associated neuropathy (statistically significant vs placebo)
- Peripheral nerves, CNS, cardiac tissue
- Moderate. Randomised controlled human trials exist but limited replication
- BPC-157
- VEGF upregulation, nitric oxide modulation, growth factor expression
- Preclinical (rodent models)
- Accelerated tendon healing (histological), gastric ulcer protection, ligament repair
- Tendons, ligaments, gastric mucosa, vasculature
- Low. Predominantly animal models, no Phase 2/3 human trials
- Anti-inflammatory (TNF-α, IL-6 suppression)
- Phase 2
- Reduced systemic inflammation markers in neuropathy models
- Immune cells, neurons
- Moderate. Human trial data limited to neuropathy indications
- Angiogenesis promotion, collagen synthesis
- Preclinical
- Increased capillary density at injury sites, enhanced biomechanical strength of repaired tissue
- Musculoskeletal, GI tract
- Low. Lack of standardised human dosing or safety trials
- No erythropoietic activity (JAK2/STAT5 pathway not activated)
- Phase 1/2 safety trials
- No measurable increase in haematocrit or red blood cell count
- Blood cells (absence of effect)
- High. Safety profile well-characterised in humans
- Dopaminergic system modulation (observed in CNS injury models)
- Behavioural changes in rodent models of CNS injury
- CNS (mechanism unclear)
- Very low. Mechanistic ambiguity, no human CNS trials